Reactive Oxygen Comes of Age: Mechanism-Based Therapy of Diabetic End-Organ Damage

Publication date: Available online 27 March 2019Source: Trends in Endocrinology & MetabolismAuthor(s): Mahmoud H. Elbatreek, Mayra P. Pachado, Antonio Cuadrado, Karin Jandeleit-Dahm, Harald H.H.W. SchmidtReactive oxygen species (ROS) have been mainly viewed as unwanted by-products of cellular metabolism, oxidative stress, a sign of a cellular redox imbalance, and potential disease mechanisms, such as in diabetes mellitus (DM). Antioxidant therapies, however, have failed to provide clinical benefit. This paradox can be explained by recent discoveries that ROS have mainly essential signaling and metabolic functions and evolutionally conserved physiological enzymatic sources. Disease can occur when ROS accumulate in nonphysiological concentrations, locations, or forms. By focusing on disease-relevant sources and targets of ROS, and leaving ROS physiology intact, precise therapeutic interventions are now possible and are entering clinical trials. Their outcomes are likely to profoundly change our concepts of ROS in DM and in medicine in general.
Source: Trends in Endocrinology and Metabolism - Category: Endocrinology Source Type: research